Annual Revenue
$556.38 M
-$1.04 B-65.20%
31 December 2023
Summary:
Novavax annual revenue is currently $556.38 million, with the most recent change of -$1.04 billion (-65.20%) on 31 December 2023. During the last 3 years, it has risen by +$533.99 million (+2385.18%). NVAX annual revenue is now -65.20% below its all-time high of $1.60 billion, reached on 31 December 2022.NVAX Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Revenue
$84.51 M
-$330.97 M-79.66%
30 September 2024
Summary:
Novavax quarterly revenue is currently $84.51 million, with the most recent change of -$330.97 million (-79.66%) on 30 September 2024. Over the past year, it has increased by +$62.45 million (+283.03%). NVAX quarterly revenue is now -86.55% below its all-time high of $628.30 million, reached on 30 September 2022.NVAX Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Revenue
$847.25 M
+$62.45 M+7.96%
30 September 2024
Summary:
Novavax TTM revenue is currently $847.25 million, with the most recent change of +$62.45 million (+7.96%) on 30 September 2024. Over the past year, it has increased by +$119.36 million (+16.40%). NVAX TTM revenue is now -50.36% below its all-time high of $1.71 billion, reached on 31 December 2022.NVAX TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NVAX Revenue Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -65.2% | +283.0% | +16.4% |
| 3 y3 years | +2385.2% | -52.8% | +12.9% |
| 5 y5 years | +1522.7% | +3271.0% | +5204.3% |
NVAX Revenue High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -65.2% | +2385.2% | -86.5% | +111.6% | -50.4% | +328.8% |
| 5 y | 5 years | -65.2% | +2881.4% | -86.5% | +111.6% | -50.4% | +5204.3% |
| alltime | all time | -65.2% | >+9999.0% | -86.5% | +111.6% | -50.4% | >+9999.0% |
Novavax Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $84.51 M(-79.7%) | $847.25 M(+8.0%) |
| June 2024 | - | $415.48 M(+342.7%) | $784.80 M(-1.1%) |
| Mar 2024 | - | $93.86 M(-63.0%) | $793.74 M(+14.5%) |
| Dec 2023 | $556.38 M(-65.2%) | $253.40 M(+1048.5%) | $693.46 M(-4.7%) |
| Sept 2023 | - | $22.06 M(-94.8%) | $727.89 M(-45.4%) |
| June 2023 | - | $424.43 M(-6702.8%) | $1.33 B(+21.8%) |
| Mar 2023 | - | -$6.43 M(-102.2%) | $1.10 B(-35.8%) |
| Dec 2022 | $1.60 B(+709.3%) | $287.83 M(-54.2%) | $1.71 B(+146.5%) |
| Sept 2022 | - | $628.30 M(+237.9%) | $692.39 M(+185.0%) |
| June 2022 | - | $185.93 M(-69.3%) | $242.93 M(-31.6%) |
| Mar 2022 | - | $604.67 M(-183.2%) | $355.02 M(+79.7%) |
| Dec 2021 | $197.58 M(+782.5%) | -$726.51 M(-506.2%) | $197.58 M(-73.7%) |
| Sept 2021 | - | $178.84 M(-40.0%) | $750.54 M(+3.0%) |
| June 2021 | - | $298.02 M(-33.4%) | $728.72 M(+56.3%) |
| Mar 2021 | - | $447.23 M(-357.7%) | $466.24 M(+1982.5%) |
| Dec 2020 | $22.39 M(+20.0%) | -$173.55 M(-210.5%) | $22.39 M(-89.1%) |
| Sept 2020 | - | $157.02 M(+341.8%) | $204.75 M(+307.6%) |
| June 2020 | - | $35.54 M(+952.4%) | $50.24 M(+178.2%) |
| Mar 2020 | - | $3.38 M(-61.7%) | $18.06 M(-3.2%) |
| Dec 2019 | $18.66 M(-45.6%) | $8.82 M(+251.7%) | $18.66 M(+16.8%) |
| Sept 2019 | - | $2.51 M(-25.3%) | $15.97 M(-24.7%) |
| June 2019 | - | $3.36 M(-15.7%) | $21.20 M(-25.9%) |
| Mar 2019 | - | $3.98 M(-35.0%) | $28.62 M(-16.5%) |
| Dec 2018 | $34.29 M(+10.0%) | $6.13 M(-20.8%) | $34.29 M(-11.1%) |
| Sept 2018 | - | $7.74 M(-28.2%) | $38.57 M(-1.6%) |
| June 2018 | - | $10.77 M(+11.6%) | $39.19 M(+11.5%) |
| Mar 2018 | - | $9.65 M(-7.3%) | $35.15 M(+12.7%) |
| Dec 2017 | $31.18 M(+103.1%) | $10.41 M(+24.7%) | $31.18 M(+19.2%) |
| Sept 2017 | - | $8.35 M(+24.1%) | $26.16 M(+24.3%) |
| June 2017 | - | $6.73 M(+18.5%) | $21.04 M(+25.1%) |
| Mar 2017 | - | $5.68 M(+5.2%) | $16.82 M(+9.5%) |
| Dec 2016 | $15.35 M(-57.6%) | $5.40 M(+67.1%) | $15.35 M(-2.9%) |
| Sept 2016 | - | $3.23 M(+29.0%) | $15.81 M(-17.2%) |
| June 2016 | - | $2.50 M(-40.6%) | $19.10 M(-37.6%) |
| Mar 2016 | - | $4.22 M(-27.9%) | $30.59 M(-15.6%) |
| Dec 2015 | $36.25 M(+18.2%) | $5.85 M(-10.3%) | $36.25 M(-2.3%) |
| Sept 2015 | - | $6.53 M(-53.4%) | $37.12 M(-4.4%) |
| June 2015 | - | $14.00 M(+41.7%) | $38.81 M(+17.3%) |
| Mar 2015 | - | $9.88 M(+46.9%) | $33.07 M(+7.9%) |
| Dec 2014 | $30.66 M(+46.6%) | $6.72 M(-18.1%) | $30.66 M(-6.2%) |
| Sept 2014 | - | $8.21 M(-0.5%) | $32.68 M(+11.7%) |
| June 2014 | - | $8.26 M(+10.7%) | $29.27 M(+19.3%) |
| Mar 2014 | - | $7.46 M(-14.7%) | $24.54 M(+17.4%) |
| Dec 2013 | $20.91 M(-5.3%) | $8.75 M(+82.2%) | $20.91 M(+25.0%) |
| Sept 2013 | - | $4.80 M(+36.0%) | $16.73 M(-5.4%) |
| June 2013 | - | $3.53 M(-7.9%) | $17.70 M(-16.8%) |
| Mar 2013 | - | $3.83 M(-16.1%) | $21.27 M(-3.7%) |
| Dec 2012 | $22.08 M(+50.3%) | $4.57 M(-20.8%) | $22.08 M(-5.5%) |
| Sept 2012 | - | $5.76 M(-18.8%) | $23.36 M(+3.3%) |
| June 2012 | - | $7.10 M(+53.0%) | $22.60 M(+22.2%) |
| Mar 2012 | - | $4.64 M(-20.6%) | $18.50 M(+25.9%) |
| Dec 2011 | $14.69 M(+4182.2%) | $5.84 M(+16.7%) | $14.69 M(+65.1%) |
| Sept 2011 | - | $5.01 M(+66.9%) | $8.89 M(+119.0%) |
| June 2011 | - | $3.00 M(+259.8%) | $4.06 M(+280.6%) |
| Mar 2011 | - | $834.00 K(+1535.3%) | $1.07 M(+211.1%) |
| Dec 2010 | $343.00 K | $51.00 K(-70.9%) | $343.00 K(-6.3%) |
| Sept 2010 | - | $175.00 K(+2400.0%) | $366.00 K(-6.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2010 | - | $7000.00(-93.6%) | $392.00 K(-5.3%) |
| Mar 2010 | - | $110.00 K(+48.6%) | $414.00 K(+27.4%) |
| Dec 2009 | $325.00 K(-69.5%) | $74.00 K(-63.2%) | $325.00 K(+1.2%) |
| Sept 2009 | - | $201.00 K(+593.1%) | $321.00 K(+2.2%) |
| June 2009 | - | $29.00 K(+38.1%) | $314.00 K(-49.9%) |
| Mar 2009 | - | $21.00 K(-70.0%) | $627.00 K(-41.1%) |
| Dec 2008 | $1.06 M(-29.7%) | $70.00 K(-63.9%) | $1.06 M(+191.5%) |
| Sept 2008 | - | $194.00 K(-43.3%) | $365.00 K(-75.4%) |
| June 2008 | - | $342.00 K(-25.3%) | $1.49 M(+14.1%) |
| Mar 2008 | - | $458.00 K(-172.8%) | $1.30 M(-0.2%) |
| Dec 2007 | $1.51 M(-12.9%) | -$629.00 K(-147.8%) | $1.30 M(+287.2%) |
| Sept 2007 | - | $1.31 M(+732.3%) | $337.00 K(+56.7%) |
| June 2007 | - | $158.00 K(-65.7%) | $215.00 K(-76.0%) |
| Mar 2007 | - | $461.00 K(-128.9%) | $896.00 K(-48.4%) |
| Dec 2006 | $1.74 M(-67.5%) | -$1.60 M(-233.9%) | $1.74 M(-50.8%) |
| Sept 2006 | - | $1.19 M(+42.2%) | $3.53 M(-16.0%) |
| June 2006 | - | $839.00 K(-35.6%) | $4.21 M(-26.0%) |
| Mar 2006 | - | $1.30 M(+554.8%) | $5.68 M(+6.4%) |
| Dec 2005 | $5.34 M(-35.3%) | $199.00 K(-89.3%) | $5.34 M(-25.7%) |
| Sept 2005 | - | $1.87 M(-19.4%) | $7.19 M(+20.3%) |
| June 2005 | - | $2.31 M(+140.6%) | $5.98 M(-10.4%) |
| Mar 2005 | - | $962.00 K(-53.0%) | $6.67 M(-25.3%) |
| Dec 2004 | $8.26 M(-29.9%) | $2.05 M(+213.3%) | $8.92 M(-18.3%) |
| Sept 2004 | - | $653.00 K(-78.3%) | $10.93 M(-24.9%) |
| June 2004 | - | $3.00 M(-6.7%) | $14.54 M(+5.3%) |
| Mar 2004 | - | $3.22 M(-20.5%) | $13.81 M(+17.2%) |
| Dec 2003 | $11.79 M(-21.5%) | $4.05 M(-5.2%) | $11.79 M(+15.1%) |
| Sept 2003 | - | $4.27 M(+87.6%) | $10.24 M(+23.4%) |
| June 2003 | - | $2.27 M(+90.5%) | $8.30 M(-20.9%) |
| Mar 2003 | - | $1.19 M(-52.2%) | $10.48 M(-30.1%) |
| Dec 2002 | $15.01 M(-37.7%) | $2.50 M(+7.3%) | $15.00 M(-19.4%) |
| Sept 2002 | - | $2.33 M(-47.8%) | $18.62 M(-12.7%) |
| June 2002 | - | $4.46 M(-21.9%) | $21.33 M(-14.0%) |
| Mar 2002 | - | $5.71 M(-6.6%) | $24.81 M(+3.1%) |
| Dec 2001 | $24.07 M(+872.4%) | $6.12 M(+21.4%) | $24.07 M(+28.3%) |
| Sept 2001 | - | $5.04 M(-36.6%) | $18.76 M(+33.1%) |
| June 2001 | - | $7.95 M(+60.0%) | $14.09 M(+109.3%) |
| Mar 2001 | - | $4.97 M(+515.4%) | $6.73 M(+172.0%) |
| Dec 2000 | $2.48 M(+106.3%) | $807.00 K(+118.1%) | $2.48 M(+4.5%) |
| Sept 2000 | - | $370.00 K(-37.1%) | $2.37 M(+12.9%) |
| June 2000 | - | $588.00 K(-17.2%) | $2.10 M(+15.9%) |
| Mar 2000 | - | $710.00 K(+1.4%) | $1.81 M(+50.8%) |
| Dec 1999 | $1.20 M(+71.4%) | $700.00 K(+600.0%) | $1.20 M(+71.4%) |
| Sept 1999 | - | $100.00 K(-66.7%) | $700.00 K(-12.5%) |
| June 1999 | - | $300.00 K(+200.0%) | $800.00 K(+33.3%) |
| Mar 1999 | - | $100.00 K(-50.0%) | $600.00 K(-14.3%) |
| Dec 1998 | $700.00 K(+40.0%) | $200.00 K(0.0%) | $700.00 K(-12.5%) |
| Sept 1998 | - | $200.00 K(+100.0%) | $800.00 K(+14.3%) |
| June 1998 | - | $100.00 K(-50.0%) | $700.00 K(0.0%) |
| Mar 1998 | - | $200.00 K(-33.3%) | $700.00 K(+16.7%) |
| Dec 1997 | $500.00 K(+400.0%) | $300.00 K(+200.0%) | $600.00 K(+100.0%) |
| Sept 1997 | - | $100.00 K(0.0%) | $300.00 K(0.0%) |
| June 1997 | - | $100.00 K(0.0%) | $300.00 K(0.0%) |
| Mar 1997 | - | $100.00 K(0.0%) | $300.00 K(0.0%) |
| Dec 1996 | $100.00 K | - | - |
| Sept 1996 | - | $100.00 K(0.0%) | $300.00 K(+50.0%) |
| June 1996 | - | $100.00 K(0.0%) | $200.00 K(+100.0%) |
| Mar 1996 | - | $100.00 K | $100.00 K |
FAQ
- What is Novavax annual revenue?
- What is the all time high annual revenue for Novavax?
- What is Novavax annual revenue year-on-year change?
- What is Novavax quarterly revenue?
- What is the all time high quarterly revenue for Novavax?
- What is Novavax quarterly revenue year-on-year change?
- What is Novavax TTM revenue?
- What is the all time high TTM revenue for Novavax?
- What is Novavax TTM revenue year-on-year change?
What is Novavax annual revenue?
The current annual revenue of NVAX is $556.38 M
What is the all time high annual revenue for Novavax?
Novavax all-time high annual revenue is $1.60 B
What is Novavax annual revenue year-on-year change?
Over the past year, NVAX annual revenue has changed by -$1.04 B (-65.20%)
What is Novavax quarterly revenue?
The current quarterly revenue of NVAX is $84.51 M
What is the all time high quarterly revenue for Novavax?
Novavax all-time high quarterly revenue is $628.30 M
What is Novavax quarterly revenue year-on-year change?
Over the past year, NVAX quarterly revenue has changed by +$62.45 M (+283.03%)
What is Novavax TTM revenue?
The current TTM revenue of NVAX is $847.25 M
What is the all time high TTM revenue for Novavax?
Novavax all-time high TTM revenue is $1.71 B
What is Novavax TTM revenue year-on-year change?
Over the past year, NVAX TTM revenue has changed by +$119.36 M (+16.40%)